Advertisement

Bladder Cancer

  • Evelyne C. C. Cauberg
  • Jean J. M. C. H. de la Rosette
  • Theo M. de Reijke
Chapter
Part of the Springer Specialist Surgery Series book series (SPECIALIST)

Abstract

In Europe, 110,500 cases of bladder cancer were diagnosed in 20081 and an estimated 70,530 will be diagnosed in the USA in 2010,2 making it the fourth most common cancer in men and twelfth most common cancer in women. The incidence is around three to four times higher among men than women and two times higher among white than black populations.3 It has been demonstrated that bladder cancer is one of the most expensive cancers in terms of lifetime costs per patient, mainly due to the lifelong need for follow-up and high recurrence rates in nonmuscle-invasive disease requiring multiple treatments.4

Keywords

Bladder Cancer Bladder Tumor Radical Cystectomy Pelvic Lymph Node Dissection Intravesical Chemotherapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer. 2010;46:765-781PubMedCrossRefGoogle Scholar
  2. 2.
    Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277-300PubMedCrossRefGoogle Scholar
  3. 3.
    Grasso M. Bladder cancer: a major public health issue. Eur Urol Suppl. 2008;7:510-515CrossRefGoogle Scholar
  4. 4.
    Madeb R, Golijanin D, Knopf J, Messing EM. Current state of screening for bladder cancer. Expert Rev Anticancer Ther. 2007;7:981-987PubMedCrossRefGoogle Scholar
  5. 5.
    Colombel M, Soloway M, Akaza H, et al. Epidemiology, staging, grading and risk stratification of bladder cancer. Eur Urol Suppl. 2008;7:618-626CrossRefGoogle Scholar
  6. 6.
    Kirkali Z, Chan T, Manoharan M, et al. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology. 2005;66:4-34PubMedCrossRefGoogle Scholar
  7. 7.
    Shokeir AA. Squamous cell carcinoma of the bladder: pathology, diagnosis and treatment. BJU Int. 2004;93:216-220PubMedCrossRefGoogle Scholar
  8. 8.
    Palou J, Rodriguez-Rubio F, Huguet J, et al. Multivariate analysis of clinical parameters of synchronous primary superficial bladder cancer and upper urinary tract tumor. J Urol. 2005;174:859-861PubMedCrossRefGoogle Scholar
  9. 9.
    Stacul F, Rossi A, Cova MA. CT urography: the end of IVU? Radiol Med. 2008;113:658-669PubMedCrossRefGoogle Scholar
  10. 10.
    Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Bohle A, Palou-Redorta J. EAU Guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol. 2008;54:303-314PubMedCrossRefGoogle Scholar
  11. 11.
    Jocham D, Stepp H, Waidelich R. Photodynamic diagnosis in urology: state-of-the-art. Eur Urol. 2008;53:1138-1150PubMedCrossRefGoogle Scholar
  12. 12.
    Bryan RT, Billingham LJ, Wallace DM. Narrow-band imaging flexible cystoscopy in the detection of recurrent urothelial cancer of the bladder. BJU Int. 2008;6:702-705CrossRefGoogle Scholar
  13. 13.
    Herr HW, Donat SM. A comparison of white-light cystoscopy and narrow-band imaging cystoscopy to detect bladder tumour recurrences. BJU Int. 2008;9:1111-1114CrossRefGoogle Scholar
  14. 14.
    Crow P, Stone N, Kendall CA, Persad RA, Wright MP. Optical diagnostics in urology: current applications and future prospects. BJU Int. 2003;92:400-407PubMedCrossRefGoogle Scholar
  15. 15.
    Engers R. Reproducibility and reliability of tumor grading in urological neoplasms. World J Urol. 2007;25:595-605PubMedCrossRefGoogle Scholar
  16. 16.
    Lokeshwar VB, Habuchi T, Grossman HB, et al. Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers. Urology. 2005;66:35-63PubMedCrossRefGoogle Scholar
  17. 17.
    Brausi M, Collette L, Kurth K, et al. Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. Eur Urol. 2002;41:523-531PubMedCrossRefGoogle Scholar
  18. 18.
    Daniltchenko DI, Riedl CR, Sachs MD, et al. Long-term benefit of 5-aminolevulinic acid fluorescence assisted transurethral resection of superficial bladder cancer: 5-year results of a prospective randomized study. J Urol. 2005;174:2129-2133PubMedCrossRefGoogle Scholar
  19. 19.
    Denzinger S, Burger M, Walter B, et al. Clinically relevant reduction in risk of recurrence of superficial bladder cancer using 5-aminolevulinic acid-induced fluorescence diagnosis: 8-year results of prospective randomized study. Urology. 2007;69:675-679PubMedCrossRefGoogle Scholar
  20. 20.
    Kriegmair M, Zaak D, Rothenberger KH, et al. Transurethral resection for bladder cancer using 5-aminolevulinic acid induced fluorescence endoscopy versus white light endoscopy. J Urol. 2002;168:475-478PubMedCrossRefGoogle Scholar
  21. 21.
    Sylvester RJ, Oosterlinck W, van der Meijden AP. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol. 2004;171:2186-90PubMedCrossRefGoogle Scholar
  22. 22.
    Sobin LH, Wittekind Ch. TNM Classification of Malignant Tumors. 6th ed. New York: Wiley Liss; 2002:196-198Google Scholar
  23. 23.
    Epstein JI, Amin MB, Reuter VR, Mostofi FK. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol. 1998;22:1435-1448PubMedCrossRefGoogle Scholar
  24. 24.
    Eble JN, Sauter G, Epstein JI, Sesterhenn IA. WHO Classification of Tumours. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. Lyon: IARCC Press; 2004Google Scholar
  25. 25.
    Herr HW. Surgical factors in the treatment of superficial and invasive bladder cancer. Urol Clin North Am. 2005;32:157-164PubMedCrossRefGoogle Scholar
  26. 26.
    Divrik RT, Yildirim U, Zorlu F, Ozen H. The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial. J Urol. 2006;175:1641-1644PubMedCrossRefGoogle Scholar
  27. 27.
    Sylvester RJ, van der Meijden AP, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006;49:466-5PubMedCrossRefGoogle Scholar
  28. 28.
    Hall MC, Chang SS, Dalbagni G, et al. Guideline for the management on nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol. 2007;178:2314-2330PubMedCrossRefGoogle Scholar
  29. 29.
    Pawinski A, Sylvester R, Kurth KH, et al. A combined analysis of European Organization for Research and Treatment of Cancer, and Medical Research Council randomized clinical trials for the prophylactic treatment of stage TaT1 bladder cancer. European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council Working Party on superficial bladder cancer. J Urol. 1996;156:1934-40PubMedCrossRefGoogle Scholar
  30. 30.
    Koya MP, Simon MA, Soloway MS. Complications of intravesical therapy for urothelial cancer of the bladder. J Urol. 2006;175:2004-2010PubMedCrossRefGoogle Scholar
  31. 31.
    Bolenz C, Cao Y, Arancibia MF, Trojan L, Alken P, Michel MS. Intravesical mitomycin C for superficial transitional cell carcinoma. Expert Rev Anticancer Ther. 2006;6:1273-1282PubMedCrossRefGoogle Scholar
  32. 32.
    van der Meijden AP, Sylvester RJ, Oosterlinck W, Hoeltl W, Bono AV. Maintenance Bacillus Calmette-Guerin for Ta T1 bladder tumors is not associated with increased toxicity: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial. Eur Urol. 2003;44:429-434PubMedCrossRefGoogle Scholar
  33. 33.
    Rischmann P, Desgrandchamps F, Malavaud B, Chopin DK. BCG intravesical instillations: recommendations for side-effects management. Eur Urol. 2000;37(suppl 1):33-36PubMedCrossRefGoogle Scholar
  34. 34.
    Rischmann P, Nicolas L, Malavaud B, Chopin D, Saint F, Colombel M. The effect of ofloxacin on bacillus Calmette-Guerin induced toxicity in patients with superficial bladder cancer: results of a randomized, prospective, double-blind, placebo controlled, multicenter study. J Urol. 2006;176:935-939. and the ITB01 study groupPubMedCrossRefGoogle Scholar
  35. 35.
    Sylvester RJ, Oosterlinck W, Witjes JA. The schedule and duration of intravesical chemotherapy in patients with non-muscle-invasive bladder cancer: a systematic review of the published results of randomized clinical trials. Eur Urol. 2008;53:709-719PubMedCrossRefGoogle Scholar
  36. 36.
    Herr HW, Morales A. History of bacillus Calmette-Guerin and bladder cancer: an immunotherapy success story. J Urol. 2008;179:53-56PubMedCrossRefGoogle Scholar
  37. 37.
    Shelley MD, Wilt TJ, Court J, Coles B, Kynaston H, Mason MD. Intravesical bacillus Calmette-Guerin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials. BJU Int. 2004;93:485-490PubMedCrossRefGoogle Scholar
  38. 38.
    Sylvester RJ, van der Meijden AP, Lamm DL. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol. 2002;168:1964-1970PubMedCrossRefGoogle Scholar
  39. 39.
    Chang SS, Cookson MS. Radical cystectomy for bladder cancer: the case for early intervention. Urol Clin North Am. 2005;32:147-155PubMedCrossRefGoogle Scholar
  40. 40.
    Hendricksen K, Witjes JA. Current strategies for first and second line intravesical therapy for nonmuscle invasive bladder cancer. Curr Opin Urol. 2007;17:352-357PubMedCrossRefGoogle Scholar
  41. 41.
    Witjes JA, Kolli PS. Apaziquone for non-muscle invasive bladder cancer: a critical review. Expert Opin Investig Drugs. 2008;17:1085-1096PubMedCrossRefGoogle Scholar
  42. 42.
    van Boven E, de Reijke TM, Vergunst H, et al. Phase II marker lesion study with intravesical instillation of Apaziquone for superficial bladder cancer: toxicity and marker response. J Urol. 2006;176:1349-1353PubMedCrossRefGoogle Scholar
  43. 43.
    Colombo R, Salonia A, Da Pozzo LF, et al. Combination of intravesical chemotherapy and hyperthermia for the treatment of superficial bladder cancer: preliminary clinical experience. Crit Rev Oncol Hematol. 2003;47:127-139PubMedCrossRefGoogle Scholar
  44. 44.
    Di Stasi SM, Giannantoni A, Giurioli A, et al. Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial. Lancet Oncol. 2006;7:43-51PubMedCrossRefGoogle Scholar
  45. 45.
    Prout GR, Marshall VF. The prognosis with untreated bladder tumors. Cancer. 1956;9:551-558PubMedCrossRefGoogle Scholar
  46. 46.
    Stein JP, Skinner DG. Radical cystectomy for invasive bladder cancer: long-term results of a standard procedure. World J Urol. 2006;24:296-304PubMedCrossRefGoogle Scholar
  47. 47.
    Koppie TM, Serio AM, Vickers AJ, et al. Age-adjusted Charlson comorbidity score is associated with treatment decisions and clinical outcomes for patients undergoing radical cystectomy for bladder cancer. Cancer. 2008;112:2384-2392PubMedCrossRefGoogle Scholar
  48. 48.
    Stein JP, Skinner DG. The role of lymphadenectomy in high-grade invasive bladder cancer. Urol Clin North Am. 2005;32:187-197PubMedCrossRefGoogle Scholar
  49. 49.
    Herr HW, Bochner BH, Dalbagni G, Donat SM, Reuter VE, Bajorin DF. Impact of the number of lymph nodes retrieved on outcome in patients with muscle invasive bladder cancer. J Urol. 2002;167:1295-1298PubMedCrossRefGoogle Scholar
  50. 50.
    Haber GP, Crouzet S, Gill IS. Laparoscopic and robotic assisted radical cystectomy for bladder cancer: a critical analysis. Eur Urol. 2008;54:54-62PubMedCrossRefGoogle Scholar
  51. 51.
    Turner WH, Studer UE. Cystectomy and urinary diversion. Semin Surg Oncol. 1997;13:350-358PubMedCrossRefGoogle Scholar
  52. 52.
    Hautmann RE. Urinary diversion: ileal conduit to neobladder. J Urol. 2003;169:834-842PubMedCrossRefGoogle Scholar
  53. 53.
    Soloway MS, van Poppel H, Thuroff J, et al. Muscle-invasive urothelial carcinoma of the bladder. Urology. 2007;69:3-16PubMedCrossRefGoogle Scholar
  54. 54.
    Kuczyk M, Turkeri L, Hammerer P, Ravery V. Is there a role for bladder preserving strategies in the treatment of muscle-invasive bladder cancer? Eur Urol. 2003;44:57-64PubMedCrossRefGoogle Scholar
  55. 55.
    Blank LECM, Koedooder K, van Os R, van de Kar M, van der Veen JH, Koning CCE. Results of bladder-conserving treatment, consisting of brachytherapy combined with limited surgery and external beam radiotherapy, for patients with solitary T1-T3 bladder tumors less than 5 cm in diameter. Int J Radiat Oncol Biol Phys. 2007; 69:454-458PubMedCrossRefGoogle Scholar
  56. 56.
    Holzbeierlein JM, Lopez-Corona E, Bochner BH, et al. Partial cystectomy: a contemporary review of the Memorial Sloan-Kettering Cancer Center experience and recommendations for patient selection. J Urol. 2004;172:878-881PubMedCrossRefGoogle Scholar
  57. 57.
    Herr HW, Dotan Z, Donat SM, Bajorin DF. Defining optimal therapy for muscle invasive bladder cancer. J Urol. 2007;177:437-443PubMedCrossRefGoogle Scholar
  58. 58.
    Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data. Eur Urol. 2005; 48:202-205CrossRefGoogle Scholar
  59. 59.
    Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. Lancet. 2003;361:1927-1934CrossRefGoogle Scholar
  60. 60.
    Winquist E, Kirchner TS, Segal R, Chin J, Lukka H. Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: a systematic review and meta-analysis. J Urol. 2004;171:561-569PubMedCrossRefGoogle Scholar
  61. 61.
    Sternberg CN, Collette L. What has been learned from meta-analyses of neoadjuvant and adjuvant chemotherapy in bladder cancer? BJU Int. 2006;98:487-489PubMedCrossRefGoogle Scholar
  62. 62.
    Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data. Eur Urol. 2005;48:189-199CrossRefGoogle Scholar
  63. 63.
    Widmark A, Flodgren P, Damber JE, Hellsten S, Cavallin-Stahl E. A systematic overview of radiation therapy effects in urinary bladder cancer. Acta Oncol. 2003;42:567-581PubMedCrossRefGoogle Scholar
  64. 64.
    Bochner BH, Montie JE, Lee CT. Follow-up strategies and management of recurrence in urologic oncology bladder cancer: invasive bladder cancer. Urol Clin North Am. 2003;30:777-789PubMedCrossRefGoogle Scholar
  65. 65.
    Oosterlinck W, Lobel B, Jakse G, Malmstrom PU, Stockle M, Sternberg C. Guidelines on bladder cancer. Eur Urol. 2002;41:105-112PubMedCrossRefGoogle Scholar

Copyright information

© Springer London 2011

Authors and Affiliations

  • Evelyne C. C. Cauberg
    • 1
  • Jean J. M. C. H. de la Rosette
    • 2
  • Theo M. de Reijke
    • 2
  1. 1.Department of Urology, Academic Medical CenterUniversity of AmsterdamAmsterdamThe Netherlands
  2. 2.Department of UrologyAcademic Medical CenterAmsterdamThe Netherlands

Personalised recommendations